{"id":70397,"date":"2026-07-22T11:20:59","date_gmt":"2026-07-22T03:20:59","guid":{"rendered":"https:\/\/flcube.com\/?p=70397"},"modified":"2026-07-22T11:21:00","modified_gmt":"2026-07-22T03:21:00","slug":"alebund-pharmaceuticals-initiates-global-phase-iib-trial-of-ap306-first-in-class-oral-pan-phosphate-transporter-inhibitor-for-hyperphosphatemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70397","title":{"rendered":"Alebund Pharmaceuticals Initiates Global Phase IIb Trial of AP306, First-in-Class Oral Pan-Phosphate Transporter Inhibitor for Hyperphosphatemia"},"content":{"rendered":"\n

Alebund Pharmaceuticals<\/strong> (HKG: 9637<\/a>) announced that the first patient has been randomized and dosed<\/strong> in its global Phase IIb multi-regional clinical trial<\/strong> (MRCT, NCT06712654) evaluating AP306<\/strong>, a first-in-class oral pan-phosphate transporter inhibitor<\/strong>, in hyperphosphatemia patients undergoing maintenance hemodialysis<\/strong>. The trial is being conducted across multiple clinical sites in the United States and China<\/strong>, with co-sponsorship from R1 Therapeutics, Inc.<\/strong><\/p>\n\n\n\n

Clinical Trial Details<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Trial Phase<\/strong><\/td>Phase IIb<\/td><\/tr>
Trial Type<\/strong><\/td>Multi-regional clinical trial (MRCT)<\/td><\/tr>
ClinicalTrials.gov ID<\/strong><\/td>NCT06712654<\/td><\/tr>
Patient Population<\/strong><\/td>Hyperphosphatemia patients on maintenance hemodialysis<\/td><\/tr>
Geographic Scope<\/strong><\/td>United States and China<\/td><\/tr>
Co-Sponsor<\/strong><\/td>R1 Therapeutics, Inc.<\/td><\/tr>
Milestone<\/strong><\/td>First patient randomized and dosed (July 21, 2026)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n